To investigate such “druggable” oncogenic genetic alterations in cervical cancer, we examined the mutational status of 16 oncogenic genes—KRAS, NRAS, HRAS, BRAF, PIK3CA, PTEN, AKT1, HER2, EGFR, FGFR2 and FGFR3 as well as FGFR3-TACC3, FGFR1-TACC1, EML4-ALK, CCDC6-RET and KIF5B-RET fusions—in a cohort of 285 Chinese patients with resected cervical cancer using reverse transcription polymerase chain reaction (RT-PCR) and direct sequencing. This evidence concerns the gene KRAS and cervical cancer.